Stay updated on Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi

Sign up to get notified when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision indicator changed from v3.7.0 to v3.7.1 while the study page remained an error page.
    Difference
    0.2%
    Check dated 2026-10-07T13:19:33.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study details with a forbidden message. This prevents viewing the trial record and related information on the page.
    Difference
    19%
    Check dated 2026-09-23T20:22:58.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.6 to v3.7.0, indicating a newer version of the page documentation or interface.
    Difference
    0.0%
    Check dated 2026-09-16T22:12:02.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The page now shows a new revision tag, v3.6.6, replacing the previous v3.6.5. This indicates a minor platform or CMS update and does not alter the study information.
    Difference
    0.0%
    Check dated 2026-09-02T18:21:24.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    A new line under Other Study ID Numbers adds a funding note for 2018.
    Difference
    0.0%
    Check dated 2026-08-26T19:50:18.000Z thumbnail image
  8. Check
    60 days ago
    Change Detected
    Summary
    A plain-language summary of the SAVANNAH study has been added to the Study Details page, outlining the rationale and design of combining osimertinib with savolitinib in EGFRm+/MET+ NSCLC after progression on osimertinib. The previous plain-language summary citation line has been removed/updated to reflect the new entry.
    Difference
    0.0%
    Check dated 2026-08-19T13:00:51.000Z thumbnail image

Stay in the know with updates to Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.